Ellis Investment Partners’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Ellis Investment Partners’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-131	Closed	-$4.04K	–	810
2022 Q2	$3K	Buy	131 +1	+0.8%	+$30	﹤0.01%	707
2022 Q1	$4K	Hold	130	–	–	﹤0.01%	711
2021 Q4	$5K	Sell	130 -600	-82%	-$28.4K	﹤0.01%	695
2021 Q3	$37K	Buy	730 +300	+70%	+$15.6K	0.01%	434
2021 Q2	$22K	Buy	430 +300	+231%	+$14.1K	0.01%	500
2021 Q1	$6K	Hold	130	–	–	﹤0.01%	640
2020 Q4	$6K	Hold	130	–	–	﹤0.01%	615
2020 Q3	$5K	Buy	+130	New	+$5K	﹤0.01%	623

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ellis Investment Partners's IDNA Position: Q3 2022 in Review

Ellis Investment Partners sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2022, closing a stake of 131 shares — an estimated $4.04K sold.

Ellis Investment Partners first reported a position in IDNA in Q3 2020 and held it in 8 quarters. The position peaked at $37K in Q3 2021. 67 funds tracked by Wall St. Rank hold IDNA as of Q3 2022.

Ellis Investment Partners reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2022 after selling out during the quarter.
Ellis Investment Partners sold 131 iShares Genomics Immunology and Healthcare ETF shares in Q3 2022, an estimated $4.04K.
Ellis Investment Partners first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2020 and held it in 8 quarters.
Ellis Investment Partners's iShares Genomics Immunology and Healthcare ETF position peaked at $37K in Q3 2021.
67 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2022.

Based on Ellis Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.